1-11 of 11
Lisa Rannigan
Close
Sort by
Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath
Journal: Blood
Blood (2013) 122 (21): 1981.
https://doi.org/10.1182/blood.V122.21.1981.1981
Published: 2013
Journal Articles

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Dorota Rowczenio, Shameem Mahmood, MRCP, FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath
Journal: Blood
Blood (2013) 122 (21): 3120.
https://doi.org/10.1182/blood.V122.21.3120.3120
Published: 2013
Journal Articles

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Shameem Mahmood, MRCP. FRCPath, Sajitha Sachchithanantham, MRCP. FRCPath, Frank Bridoux, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontanna, MD, Carol Whelan, MD, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath
Journal: Blood
Blood (2013) 122 (21): 3143.
https://doi.org/10.1182/blood.V122.21.3143.3143
Published: 2013
Journal Articles

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

Ashutosh D. Wechalekar, Stefan O. Schonland, Efstathios Kastritis, Julian D. Gillmore, Meletios A. Dimopoulos, Thirusha Lane, Andrea Foli, Darren Foard, Paolo Milani, Lisa Rannigan, Ute Hegenbart, Philip N. Hawkins, Giampaolo Merlini, Giovanni Palladini
Journal: Blood
Blood (2013) 121 (17): 3420–3427.
https://doi.org/10.1182/blood-2012-12-473066
Published: 2013
Journal Articles

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Christopher P Venner, MD, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Shameem Mahmood, MBBCh. FRCPath, Simon DJ Gibbs, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD
Journal: Blood
Blood (2012) 120 (21): 2966.
https://doi.org/10.1182/blood.V120.21.2966.2966
Published: 2012
Journal Articles

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

Shameem Mahmood, MBBCh. FRCPath, Christopher P. Venner, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath
Journal: Blood
Blood (2012) 120 (21): 2978.
https://doi.org/10.1182/blood.V120.21.2978.2978
Published: 2012
Journal Articles

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

Brief Report
Christopher P. Venner, Thirusha Lane, Darren Foard, Lisa Rannigan, Simon D. J. Gibbs, Jennifer H. Pinney, Carol J. Whelan, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh D. Wechalekar
Journal: Blood
Blood (2012) 119 (19): 4387–4390.
https://doi.org/10.1182/blood-2011-10-388462
Published: 2012
Journal Articles

ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis

Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Ashutosh Wechalekar, MD, Simon Gibbs, MD, Jennifer Pinney, MD, Christopher P Venner, MD, Sanjay Banypersad, MD, Helen Lachmann, MD, Philip N Hawkins, MD, Julian D Gillmore, MD
Journal: Blood
Blood (2011) 118 (21): 992.
https://doi.org/10.1182/blood.V118.21.992.992
Published: 2011
Journal Articles

Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,

Christopher P. Venner, MD, Julian D Gillmore, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Simon DJ Gibbs, Jennifer Pinney, MD, Carol Whelan, Helen Lachmann, MD, Philip N Hawkins, Ashutosh Wechalekar, MD
Journal: Blood
Blood (2011) 118 (21): 3975.
https://doi.org/10.1182/blood.V118.21.3975.3975
Published: 2011
Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,

Christopher P. Venner, MD, Julian D Gillmore, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Simon DJ Gibbs, Jennifer Pinney, MD, Carol Whelan, Helen Lachmann, MD, Philip N Hawkins, Ashutosh Wechalekar, MD
Journal: Blood
Blood (2011) 118 (21): 3978.
https://doi.org/10.1182/blood.V118.21.3978.3978
Published: 2011
Journal Articles

European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease

Ashutosh Wechalekar, MD, Stefan O Schonland, MD, Efstathios Kastritis, Philip N Hawkins, Meletios A. Dimopoulos, Paola Russo, MD, Thirusha Lane, RN, Andrea Foli, MD, Darren Foard, RN, Paolo Milani, MD, Lisa Rannigan, RN, Ute Hegenbart, Julian D Gillmore, Giampaolo Merlini, Giovanni Palladini
Journal: Blood
Blood (2011) 118 (21): 995.
https://doi.org/10.1182/blood.V118.21.995.995
Published: 2011